COIOSDeep risk insights through multi-disciplinary research across the globe
people walking on sidewalk near red and brown building during daytime
Item refines Peer-reviewed Added

Injection-schedule adherence to long-acting cabotegravir plus rilpivirine in Spain

Among 3280 virologically suppressed adults in Spain, 70.4% received every evaluable injection within ±7 days; 0.7% had suboptimal adherence.

The study examined injection-schedule adherence to long-acting cabotegravir plus rilpivirine in virologically suppressed adults with HIV in Spain. The nationwide RELATIVITY cohort combined retrospective and prospective data, counting injections given within ±7 days of target. Of 3280 evaluable participants, 70.4% received all injections on time, 28.9% received 90–99.9% on time and 0.7% under 90%. At least one late injection occurred in 38.2% and two or more in 13.3%; virological failure stayed infrequent. In adjusted models, centre volume, prior ART duration, foreign nationality, BMI and comorbidity burden had small-to-moderate associations with late injections. The design was observational and partly retrospective, so it shows associations rather than causes.

Why it is interesting: Long-acting injections move adherence from patient pill-taking to clinic scheduling. In this large routine-care cohort, only 0.7% had suboptimal adherence, though single late doses were common.

Source
AIDS, 23 October 2026
Paper
Controlled adherence with long-acting injectable cabotegravir plus rilpivirine: determinants and clinical impact of injection-schedule adherence in the Spanish RELATIVITY cohort
Authors
Buzón-Martín L, Cabello-Clotet N, Gea-Grela A, Cuevas G, Galindo MJ, Martínez RM et al.
DOI
10.1097/QAD.0000000000004629
Type
Peer-reviewed article
Design
Nationwide observational cohort (RELATIVITY, Spain), retrospective plus prospective follow-up, n=3,349 (3,280 evaluable), proportion-of-days-covered adapted to injections, Kaplan-Meier and Cox models
Verdict
Refines prior evidence
Driver
Infection and pandemics
Driver
Adherence and persistence
Free full text
Free to read at the publisher

Other drivers in Behavioural science

  • Diet, exercise and sleep

    What people eat and how much they move: what the measured evidence says each does to mortality, and what has been shown to change either.

    2 this week
  • Smoking and vaping

    How far smoking has fallen and how many deaths it still causes, what vaping is doing to the people who take it up, and what generational bans will show.

    4 this week
  • Alcohol and drug use

    What is happening to deaths from alcohol, drugs and suicide, whether they move together, and how much of it is behaviour and how much circumstance.

    3 this week
  • Social connection

    Isolation, loneliness and mortality: what the evidence shows, how far the relationship is causal, and what interventions have shown.

    None this week Earlier →
  • Infection and pandemics

    Infection and pandemics: the risks, and how well prepared we are

    8 this week
  • Adherence and persistence

    Whether a treatment is actually taken, for how long, and what changes either.

    2 this week